board of directors management team technologies circassia technologies toleromune allergy immunotherapies our toleromune technology identifies unique combinations of synthetic peptides to treat allergies with a short course of therapy . particle engineered respiratory therapies our proprietary particle engineering technologies underpin our portfolio of respiratory product candidates . niox feno testing our niox products accurately measure the concentration of fractional exhaled nitric oxide feno in asthma patients breath to help evaluate underlying airway inflammation . technologies publications products pipeline pipeline products allergy immunotherapiescat allergygrass allergyhouse dust mite allergyragweed allergyasthma therapiesflixotide flovent substituteseretide advair substituteserevent substitutecopd treatmentslama novel formulationtriple combination pipeline chart commercial opportunity investors regulatory news share price summary share price chart analyst coverage financial reports financial calendar registrars corporate governance warning to shareholders email alerts investor contacts historical share offerings careers career opportunities uk opportunitiesus opportunitieseuropean opportunities opportunities careers contacts apply online media latest press release interim results for the six months ended 30 june 2016 27th september 2016 press releases presentations webcasts & audio image library media contacts contacts locations departments conferences a world class specialty biopharmaceutical company our ambition is to become a leading specialty biopharmaceutical company meeting the needs of patients around the world . with our market leading asthma management products and development pipeline of treatments for allergy asthma and copd we re making good progress towards achieving our goal . our technologies we re using our proprietary technologies to develop short course treatments for allergy and a range of therapies for asthma and chronic obstructive pulmonary disease copd . our products our novel niox products are used to assist asthma diagnosis direct treatment and help with ongoing monitoring . our pipeline we re developing a broad range of products and our lead asthma treatment was recently approved in the uk . about us we re a world class specialty biopharmaceutical company focused on allergy asthma and copd . careers we re a rapidly growing company with a range of exciting career opportunities . investors circassia is listed on the london stock exchange under the ticker cir . press releases interim results for the six months ended 30 june 2016 27th september 2016 notice of interim results 15th july 2016 circassia announces top line results from cat allergy phase iii study 20th june 2016 more press releases share price full share price chart annual report read the annual report pdf 2016 circassia . all rights reserved . legal notice privacy policy us eu data privacy site map